Bartolacci, J. G.
Behun, M. N.
Warunek, J. P. http://orcid.org/0000-0002-5430-9834
Li, T.
Sahu, A.
Dwyer, G. K.
Lucas, A.
Rong, J.
Ambrosio, F.
Turnquist, H. R.
Badylak, S. F. http://orcid.org/0000-0003-3555-0689
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR073527, R01AR073527)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (F30AI147437)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL22489)
Article History
Received: 11 September 2020
Accepted: 4 January 2024
First Online: 27 January 2024
Competing interests
: The authors declare the following competing interest: S. Badylak is the chief scientific officer for ECM Therapeutics, a company that has license rights to intellectual property that involves matrix-bound nanovesicles and for which he is a named inventor. The remaining authors declare no competing interests.